Trials / Withdrawn
WithdrawnNCT04079231
Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
A Comparative Double Masked, Two-Arm, Randomized, Multicenter, Phase IIIb Study Analyzing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (BUZZARD)
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 110 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
Detailed description
In this 48-week, randomized, double-masked, multicenter, active controlled study, consenting patients will be randomized in a 1:1 ratio to one of the two treatment arms and attend 14 planned visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brolucizumab | Intravitreal Injection |
| DRUG | Aflibercept | Intravitreal injection |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2023-01-31
- Completion
- 2023-01-31
- First posted
- 2019-09-06
- Last updated
- 2021-03-04
Source: ClinicalTrials.gov record NCT04079231. Inclusion in this directory is not an endorsement.